Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin's Lymphoma
Links shared publicly online about this topic.
- 1,772total visits
Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.
View full resource at news-medical.net
Tags: Lymphoma, Non-Hodgkin Lymphoma, Drug, Pharma, Health Insurance, Medicare, FDA, Oncology
Most Recently Shared on September 5, 2009 at 6:57 am By:
Medicare News: Spectrum's ZEVALIN expanded label receives FDA approval for treating non-Hodgkin’s .. http://digg.com/u1C1sH
Advertisement
